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Prostate cancer is a highly heritable molecularly and clinically heterogeneous disease.
To discover germline events involved in prostate cancer predisposition, we develop a
computational approach to nominate heritable facilitators of somatic genomic events in the
context of the androgen receptor signaling. Here, we use a ranking score and benign prostate
transcriptomes to identify a non-coding polymorphic regulatory element at 7p14.3 that
associates with DNA repair and hormone-regulated transcript levels and with an early
recurrent prostate cancer-speciﬁc somatic mutation in the Speckle-Type POZ protein (SPOP)
gene. The locus shows allele-speciﬁc activity that is concomitantly modulated by androgen
receptor and by CCAAT/enhancer-binding protein (C/EBP) beta (CEBPB). Deletion of this
locus via CRISPR-Cas9 leads to deregulation of the genes predicted to interact with
the 7p14.3 locus by Hi-C chromosome conformation capture data. This study suggests that a
polymorphism at 7p14.3 may predispose to SPOP mutant prostate cancer subclass through a
hormone-dependent DNA damage response.
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Prostate cancer (PCa) is the second most frequent cancer inmen causing each year more than 250,000 deathsworldwide. From a genomic perspective PCa is a collection
of molecular subclasses1. Approximately 58% of risk for prostate
cancer has been estimated to be due to inherited genetic factors2.
Genome-wide association studies have identiﬁed more than 100
common single-nucleotide polymorphisms (SNPs) associated
with the risk of developing PCa3. Most of these variants reside in
non-coding regulatory regions and may affect the transcription
factors (TFs)-binding afﬁnity4. Androgen receptor (AR) regulates
genes expression in multiple tissues and diseases, by targeting
binding elements in promoters and distant enhancers. A recent
PCa whole-genome sequencing study revealed a signiﬁcant
correspondence between DNA breakpoints and AR-binding sites
implicating an inter-play between hormone regulation and
genomic events5. These studies highlight an important role
of androgens in the initiation and development of PCa. Indeed,
at the earliest time point of clinical presentation, PCa already
harbors a range of genomic lesions1 possibly due to DNA repair
defects. We reasoned that, over a man’s lifetime, heritable variants
could potentially predispose to genomic instability in the context
of variable AR signaling leading to early PCa-speciﬁc somatic
genomic events. To test this hypothesis, we interrogated the
constellation of transcriptomic changes in benign prostate cells
for clues as to how genetic variants could impact prostate cancer
development through alterations in the expression of DNA repair
genes and hormone-regulated genes. Here we report a link
between an inherited non-coding variant and prostate cancer
somatic mutations through the interrogation of large cohorts of
human data and experimental support of the functional activity
of the variant locus.
Results
In silico selection of germline triggers of somatic mutations.
To quantitatively assess the predisposition to genomic changes in
the context of AR signaling, we developed an approach to
nominate potential heritable facilitators (referred hereafter as
triggers) of somatic genomic events. We considered human
variants within functionally active regions of the genome deﬁned
by the Encyclopedia of DNA Elements (ENCODE) histone mark
ChIP-seq data6, and established a ranking score, the trigger score,
which quantiﬁes the fraction of the transcriptome putatively
modulated by each human variant leveraging individuals’
genotypes and transcript levels (Fig. 1a). The trigger score-unlike
eQTL-based approach-only queries a predeﬁned set of transcripts
and ranks the variants for their likelihood to play a role in
predisposition to cancer hallmarks7. When applied to a RNA-seq
data set comprising more than 200 samples including benign
human prostate tissue from The Cancer Genome Atlas (TCGA)
and samples from the 1000 Genomes Project with known
genotype at variants in transcriptionally active regulatory
elements4, 6, 8, the trigger score nominated 300 polymorphisms
linked to DNA repair and hormone-regulated genes (Fig. 1b,
Supplementary Data 1–3). Sixty-nine of those sites had a minimal
trigger score in non-prostate samples (Supplementary Data 3).
Several recent genomic studies now establish PCa as best being
regarded as a collection of molecularly deﬁned cancers -similar
to breast and lung cancer- with major subclasses deﬁned by
either ETS gene fusions (most commonly TMPRSS2-ERG
rearrangements), SPOP or FOXA1 single-nucleotide
mutations1, 9, 10. These genomic events are recognized as early
clonal events that are recurrent in primary untreated prostate
cancers9, 11, and are mainly prostate speciﬁc. To explore
genotype/phenotype relationship for these common prostate
cancer mutations, we assembled a data set comprising 539
prostate tumors from three recent studies1, 9, 11, and observed
47.2, 12.1, and 5.4% incidence, respectively, (Supplementary
Data 4). To test the relationship between the trigger candidates
and the three somatic phenotypes, we used a computational in-
silico cross-validation strategy that limits false positives results
and implements multiple discovery and validation partitions from
the entire cohort preserving somatic event incidence. No signal
was detected for the FOXA1 phenotype and, surprisingly, no
signal was observed for the largest genomic subclass deﬁned by
the ETS rearrangement phenotype (i.e., TMPRSS2-ERG). In
contrast, a polymorphic site on 7p14.3 (rs1376350) was
signiﬁcantly associated with SPOP somatic mutations in 97.4%
of the partitions with any positive signal (Fig. 1b, Supplementary
Data 5 and Supplementary Table 1). When interrogating the
whole prostate cancer cohort (N= 539 patients, Fig. 1c and
Table 1), the association with the phenotype was highly
signiﬁcant (P= 6.7e-06, OR= 4.83 logistic regression analysis).
Further analyses including SPOP wild-type samples of the
prostate cancer Tyrol PSA screening cohort12 and of the 1000
Genomes Project conﬁrmed the association (P= 1.22e-08, OR=
5.54 logistic regression analysis). Moreover, the genotype/
phenotype relationship with SPOP mutation was conﬁrmed in
an independent non-Caucasian prostate cancer cohort of Korean
men (P= 4e-02, OR= 5.84 logistic regression analysis)13, indicat-
ing that this phenomenon is not limited to Caucasian male
populations but rather may extend across multi-ethnic popula-
tions (Table 1 and Fig. 1d). No association was detected between
the genotype and the total number of somatic single-nucleotide
variants (SNVs) in the tumor, but we observed increased somatic
genomic burden in men with the minor allele associated with
SPOP mutant prostate cancer (Supplementary Fig. 1). Linkage
disequilibrium analysis on the 1000 Genomes Project data did not
reveal variants in functional or coding regions linked to
rs1376350 across populations (Supplementary Data 6).
Regulatory impact of 7p14.3 variant. Fourteen DNA repair
genes and 15 hormone-regulated genes contributed to the high
trigger score for the 7p14.3 variant (Supplementary Data 7), of
which DAZAP2, DDX18, SET, and XRCC5 were also signiﬁcantly
deregulated in SPOP mutant as compared to SPOP wild-type
human prostate carcinoma cases (Supplementary Fig. 2).
Interestingly, 93% of DNA repair and hormone-regulated
transcripts are downregulated by the 7p14.3 variant
minor allele; this proportion is signiﬁcantly higher than the
fraction of transcripts downregulated by the 7p14.3 minor allele
in the whole transcriptome (48%, P= 3.2e-06 proportion test).
Protein–protein-interaction (PPI) network data projected on the
fraction of the whole transcriptome modulated by the variant
(Supplementary Fig. 3) revealed a connected subnetwork of
signiﬁcant relative size when compared to the same analysis for
each polymorphic transcriptionally active regulatory element
considered in the study (P= 1e-02 resampling, Supplementary
Fig. 4). Genes in the subnetwork are signiﬁcantly enriched for
gene expression and translation pathways terms (FDR= 5.1e-17
and FDR= 1.6e-07, respectively) and, as expected, for hormone-
regulated and DNA repair genes (P= 0.048, P= 6e-04
permutation test). In addition, of all the 57 oncogenes14 including
39 TFs we queried for targets enrichment15, c-MYC resulted as
the only signiﬁcant one (FDR= 0.005; P< 1e-05 permutation
test) with a majority of downregulated targets (P= 0.018
proportion test). Overall, this suggests a broad transcriptional
regulatory impact of the variant 7p14.34.
In vitro validation. We then veriﬁed the activity of the
polymorphic regulatory region containing the 7p14.3 variant with
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an in vitro luciferase assay in two model systems, AR-negative
(PC-3) and AR-positive (LNCaP) prostate cancer cells (Fig. 2a).
In PC-3 cells, signiﬁcantly increased activity was observed in the
presence of the minor allele (adenine) associated with SPOP
mutation compared to the ancestral one (guanine). In contrast,
inhibitory activity was observed in LNCaP cells, suggesting
differential effects of the variant with respect to AR status.
TF DNA-binding site (TFBS) motifs analysis demonstrated an
AR consensus motif at the variant locus with the minor but not
with the ancestral allele (Supplementary Fig. 5a, Supplementary
Data 8). In addition, we identiﬁed a consensus motif for the CEBP
family (Supplementary Fig. 5b), which includes known AR co-
repressors16. RNA-seq data show high levels of CEBPB tran-
scripts in multiple prostate tissue cell lines and a marked anti-
correlation with AR levels in human prostate cancers (N= 319, P
= 8e-18 Pearson correlation, Supplementary Fig. 6a, b). A less
stringent TFBS search in a wider genomic region revealed addi-
tional CEBPB-speciﬁc consensus motifs in proximity of the var-
iant locus. In addition, we found overlapping CEBPB and AR
motifs ~70 bp downstream the variant and a CEBPB putative-
binding site ~180 bp upstream the variant, along with motifs for
MAFB and c-MYC TFs, known to co-localize with CEBPB17
(Supplementary Data 8). We, therefore, investigated the effect of
AR over-expression on TFs binding at the 7p14.3 locus.
ChIP-qPCR experiments showed AR and CEBPB recruitment
at the site of interest upon AR over-expression (KLK3 and IL-6
were used as positive controls, respectively) (Fig. 2b). Based on
the wider TFBS search results, we also veriﬁed the recruitment of
c-MYC at the 7p14.3 region upon AR over-expression and
dihydrotestosterone (DHT) treatment (Supplementary Fig. 7). To
address the potential functional consequences of AR and CEBPB
binding to the polymorphic site, we examined the effects of
modulating androgenic signaling. We observed decreased
responsiveness of the reporter constructs in PC-3 cells upon AR
overexpression and DHT treatment (Supplementary Fig. 8),
whereas loss of repressive activity upon AR knock-down in
LNCaP cells was seen (Supplementary Fig. 9a, b). PC-3 cells also
showed a decreased enhancer activity upon CEBPB
over-expression, which was even stronger upon AR
over-expression (Fig. 2c), and an increase in enhancer transacti-
vation upon CEBPB knock-down (Fig. 2d). The construct
harboring the minor allele (A) showed the same behavior, while
eliciting higher enhancer activity at all conditions (Supplementary
Fig. 10). These data suggest that CEBPB may act as an AR
co-repressor at the variant locus, potentially through its
recruitment by AR and that the 7p14.3 locus may undergo
allele-dependent TF binding altering the expression of DNA
repair and hormone-dependent genes.
Structural associations with 7p14.3 locus. To further
demonstrate that the 7p14.3 region is functionally active, we
deleted 731 bp of genomic sequence around the site via
CRISPR-Cas9 (Supplementary Data 9) in PC-3 cells and
sequenced their transcriptomes. Differential transcript expression
analysis of edited vs. non-edited cells (control cells) showed
enriched deregulation when compared to the same analysis in
edited vs. edited and control vs. control (P= 1e-04 and P= 3e-05
Mann–Whitney test, respectively, Supplementary Fig. 11) as
validated by real-time PCR in selected genes (Supplementary
Fig. 12). The fraction of deregulated genes that showed
upregulation resulted on average in 70%, 65%, and 62%,
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Fig. 1 Genetic predisposition to SPOP mutant prostate cancer. a Schematic representation of the trigger score computation. The number of DNA repair
(DnaRep) and hormone-regulated genes (HormReg) from healthy prostate cells that are modulated by a functional variant are combined into a ranking
score that measures the likelihood to observe a prostate-speciﬁc early somatic event. The combination of the two variables demonstrate the nontrivial
impact that DNA repair and hormone-regulated genes have on trigger score ranking. b Trigger score distribution (left) across all considered functional
variants; top ranked variants are highlighted. Genotype/phenotype analysis (right) is performed on random partitions of the data set into discovery and
validation sets for three early recurrent prostate cancer lesions (SPOP mutations, FOXA1 mutations, and TMPRSS2-ERG rearrangement). An 7p14.3 variant
associated to SPOP was implicated in 97.4% of all collected associations (187 of the 192 partitions for which association signal was detected, red portion of
the ring plot). No variants in the partition space for FOXA1 and TMPRSS2-ERG lesions were identiﬁed. c Genotype/SPOP phenotype data on the whole study
set is shown (7p14.3 variant highlighted, dominant test considered). d Hematoxylin and eosin stained prostate cancer frozen tissue sections and
corresponding SPOP Sanger sequencing are shown for a patient carrying the 7p14.3 variant ancestral genotype and lacking SPOP mutation (left) and a
patient carrying the 7p14.3 variant minor allele genotype and harboring SPOP F133L mutation (right)
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respectively. Along chromosome 7 the analysis between edited vs.
control cells, but not edited vs. edited or control vs. control,
showed signiﬁcant concordance with genes predicted to
physically interact with the 7p14.3 locus by previously generated
Hi-C chromosome conformation capture data from
benign prostate cells18 (Fig. 3a, b, P= 1e-05 and P= 5e-09
Mann–Whitney test, respectively). Validation of ETV1, NT5C3A
and IGFBP3 deregulation upon deletion of 7p14.3 locus is shown
(Fig. 3b, c) further supporting medium-range interaction.
Discussion
Over the past 15 years, numerous non-coding SNPs have been
linked to the susceptibility to developing prostate cancer3, the
second most frequent cancer in men causing each year more than
250,000 deaths worldwide, with modest albeit highly signiﬁcant
effects. Evidence of predisposition to TMPRSS2-ERG prostate
cancer subtype was previously tested in small familial or sporadic
small cohorts19–21. Recently, two out of 27 common prostate
cancer risk variants were found associated with modest signal to
the ETS subclass22. Here we tested a speciﬁc hypothesis on large
collections of human prostate tissues and identiﬁed a strong
association with an emerging class involving mutation in the
SPOP gene. Its phenotype is related to DNA repair and
AR dysfunction11, 23 and deﬁnes a distinct molecular class as
conﬁrmed by the TCGA prostate adenocarcinoma publication1.
Our ﬁndings suggest that the genetic component of this common
disease is linked, at least partially, to speciﬁc molecularly deﬁned
sub-classes through the modulation of AR targets and DNA
repair genes. SPOP mutations that predominately involve
hotspots located in the MATH substrate binding domain of the
protein are prostate cancer speciﬁc24. Using in vitro models, we
recently linked the SPOP mutant prostate cancer to genomic
instability due to defects in homologous repair23.
While the mechanism linking the 7p14.3 variant and SPOP
mutation remains elusive and future studies should investigate
the role of the allele in the emergence of SPOP somatic mutations,
we propose a relevant role in cancer predisposition of non-coding
variants that lead to allele-speciﬁc transactivation of central TF
programs with age dependent and tissue-speciﬁc effect8, 21, 25
manifesting in early somatic genomic events. This study has
potential important implications for the aging male whose
testosterone levels change with advancing age, where a subtle
differential effect might become signiﬁcant to the cell (Fig. 4,
Supplementary Fig. 13) and facilitate or accelerate the initiation of
tumorigenesis in hormone sensitive tissues.
Findings from this study may be generalizable to other cancer
subtypes. The predisposition to neoplastic development manifests
in a combination of genomic and epigenetic events over time.
Unlike many of the model systems that require results to occur in
short periods of time, neoplastic development is a ﬁtness selection
process. As suggested with the 7p14.3 allele in this study,
association with disease-speciﬁc pathways potentially enables a
cascade of events over time to provide an advantage for cells that
are hormonally regulated, for example, to undergo more frequent
DNA damaging events that are not repaired. As in the current
study, this genetic predisposition may positively select for SPOP
mutations as they accelerate the DNA damage phenotype with a
complex interplay of multiple TFs at the site of interest involving
AR, CEBPB, and possibly c-MYC. Future large scale studies
should explore the role of germline trigger events to announce
driver somatic mutations.
Methods
Selection of human genome variants in functional regions. ChIP-Seq ENCODE
data were queried for 16 cell-lines selected based on availability of H3K4m1,
H3K4m3, and H3K27ac regions of signal enrichment data (broadPeak format).
The cell line set includes GM12878, H1-hESC, Hela-S3, HepG2, HMEC, HSMM,
HSMMtube, HUVEC, K562, Monocytes-CD14 + , NHA, NHDF-Ad, NHEK,
NHLF, Osteobl, Dnd41. Consensus regions were determined for all three marker
signals. Speciﬁcally, for each marker the consensus was generated as the overlap of
all regions with enrichment signal above ﬁve detected in at least two cell lines as
follow: (i) retain a region if it overlaps at least another cell line region for at least
50% of its length; (ii) concatenate the coordinates of regions from step i; (iii) sort
and merge retained regions. BEDTools26 and ENCODE data as of January 2014
were used. Next we considered known SNVs that were commonly genotyped in
prostate tumors and matched healthy DNA that demonstrated high quality
hybridization signal9, 12 and the interim TCGA prostate cancer cohort1.
Variants within functional regions supported by presence of H3K4me1 and
H3K27ac consensus signals and absence of H3K4me3 consensus signal were
selected retaining only one among multiple completely dependent variants (linkage
disequilibrium data provided by the International HapMap Project (http://hapmap.
ncbi.nlm.nih.gov/) for all populations was used; we deﬁne two variants to be
completely dependent when both D’ and R2 measures are equal to 1). A total of
21,364 variants in functional regions were ﬁnally considered (hereafter referred to
as ‘‘functional variants’’).
Selection of DNA repair genes and hormone-regulated genes. DNA repair
genes list was obtained from the Human DNA Repair Genes database (http://
sciencepark.mdanderson.org/labs/wood/dna_repair_genes.html) and an additional
curated list (Supplementary Data 1) (N= 180). The list of hormone-regulated
genes was obtained from27 (N= 330). Speciﬁcally, data for three biological
replicates of LNCaP cells treated with small interfering RNA (siRNA) targeting
AR and corresponding controls were considered (GSM288299, GSM288300,
GSM288301, GSM288293, GSM288294, GSM288295) and for each replicate
differentially expressed genes were selected as follows: (i) selection and quintile
normalization of genes with reported detection P-values < 5% both in AR treated
Table 1 Association signal of variant 7p14.3 with SPOP somatic phenotype
Cohort AA+AG
carriers
GG
carriers
MAF Comparison
with SPOP.wt
tumors
Comparison
with tyrol
controls
(N= 1,014)
Comparison
with tyrol
extended
controls
# (N= 1,291)
Comparison with
1000 Genomes
Project controls
## (N= 2,504)
Comparison
with all controls
## (N= 3,795)
OR P OR P OR P OR P OR P
Adenocarcinomas discovery 24 217 0.052 5.75 3.0e-04 10.47 1.1e-07 10.2 9.1e-08 5.44 3.0e-05 6.38 4.5e-06
Adenocarcinomas validation 23 217 0.048 4.45 4.1e-03 8.22 8.8e-06 7.9 9.1e-06 4.04 1.5e-03 4.73 4.0e-04
Adenocarcinomas complete 47 434 0.050 4.83 6.7e-06 9.20 1.54e-10 8.9 7.4e-11 4.72 3.0e-07 5.54 1.2e-08
Adenocarcinomas EUR only 42 373 0.052 4.96 3.7e-05 10.07 1.3e-09 9.75 7.4e-10 7.86 1.1e-07** 8.44 7.8e-10**
Validation Korean 19 61 0.206 5.84 4.0e-02 – – – – 4.78 4.3e-02*** – –
Results refer to logistic regression analysis using dominant model corrected for age and prostate-speciﬁc antigen (PSA). First three rows show data from a random partition (discovery and validation)
and the complete data set; columns include signal upon data set extension to controls from the Tyrol PSA Screening Cohort and the 1000 Genomes Project individuals collection. Data is also reported
for EUR descent individuals only and for an independent cohort of Korean patients (EAS from 1000 Genomes Project collection included as controls). #ETS positive/SPOP.wt tumors and controls,
##analysis not corrected for age and PSA, **EUR individuals only included (N= 503), ***EAS individuals only included (N= 504).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00046-0
4 NATURE COMMUNICATIONS |8:  48 |DOI: 10.1038/s41467-017-00046-0 |www.nature.com/naturecommunications
and control cells; (ii) Selection of genes with absolute-change, i.e., log2(treated/
control), equal or greater than 1. The ﬁnal hormone-regulated gene list
(Supplementary Data 2) is obtained by merging the genes differentially expressed
in at least one of the three replicates.
Somatic phenotype data sets. Whole-exome or whole-genome sequencing data
from prostate cancer tissue samples was queried for early somatic lesions1, 9, 11.
Patients with relevant clinical annotations (age, PSA), functional variant genotypes
and lesion status for SPOP (N= 539, 12.1% mutated), TMPRSS2-ERG (N= 451,
47.2% rearranged) and FOXA1 (N= 520, 5.4% mutated) were included in the study
(N total = 539, Supplementary Data 4). Variants genotypes were determined using
standard APT tools 1.16.1 pipeline from Affymetrix SNP 6.0. As all data sets used
clinically localized prostate cancer cases, none of these data sets have meaningful
clinical follow up data, which would require ten or more years.
Ethnicity analysis. Ethnicity of all individual’s samples was inferred using an
approach based on inspection of differential germline variants genotype. First, by
combining genotype data of individuals with known ethnicity a reference model is
built; genotype data by the International HapMap Project was used. A target model
is then created using genotype data from all 539 individuals in the somatic data set.
Principal component analysis (PCA) is then performed by means of smart pca
module28 on aggregated target and reference models genotype data. Euclidean
space deﬁned by the ﬁrst two PCA components is then inspected to, ﬁrst, generate
smallest convex sets identifying main ethnic groups (EUR, AFR, EAS, AMR, and
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Fig. 2 Functional characterization of 7p14.3 variant. a Luciferase assays were performed on PC-3 and LNCaP cells transfected with pGL4.26 vectors
containing 7p14.3 (A or G allele, represented in light grey and dark grey, respectively) or empty vector (white); mean± s.d. of three biological replicates. b
PC-3 cells were transfected with pCMV_Empty (solid bars) or pCMV_AR (dashed bars) vectors; AR (left) or CEBPB (right) chromatin binding at 7p14.3 locus
in PC-3 cells were evaluated by ChIP-qPCR. Occupancy level at KLK3 enhancer and IL-6 promoter was used as positive control of AR and CEBPB,
respectively. Data are represented as mean± s.d. of two biological replicates. c Luciferase assays on PC-3 cells co-transfected with pCMV6_CEBPB and/or
CMV_AR (dashed bars) along with the different pGL4.26 reporter vectors described above. The enhancer activity is inhibited upon CEBPB overexpression.
The inhibition becomes stronger upon AR over-expression. Data are represented as mean± s.d. of two biological replicates. d Luciferase assays on PC-3
cells transfected with siRNA against CEBPB or scrambled siRNA. Then, cells were co-transfected with pCMV_Empty or pCMV_AR vectors along with the
pGL4.26 reporter vectors described above. Data are represented as mean± s.d. of two biological replicates. Where indicated, cells were treated for 16 h
with EtOH or DHT. *P< 0.05,.**P< 0.01, ***P< 0.005, Student’s t-test
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SAS) and then to annotate the ethnicity of the 539 individuals in the somatic data
set. Individuals within an ethnic group set are annotated with the corresponding
ethnicity; individuals outside the ethnic group sets are annotated with the nearest
(Euclidean distance) ethnic group. The annotation of ethnic background in our
cohort is reported in Supplementary Data 4.
Korean cohort. Prostate cancer patients of Korean descent were previously
annotated for SPOP mutations13. Individuals with relevant clinical annotations
(age and PSA) and SPOP mutation status (N= 80, 8.7% SPOP mutated) were
retained. The rs1376350 variant genotype was assessed by TaqMan assay
(Supplementary Data 4).
Control cohorts. Genotype data for the rs1376350 study variant was retrieved for
2504 individuals from the 1000 Genomes Project FTP repository (Release
20130502). Genotype data and clinical information for 1903 individuals from the
Tyrol Early Prostate Cancer Detection Program cohort12, 29 were queried. This set
includes 1036 healthy controls and additional 492 individuals considered as SPOP
wild type (Supplementary Data 4). No statistically signiﬁcant genotype/phenotype
association was found when testing the 7p14.3 variant in the Tyrol cohort
against prostate cancer risk (P= 0.47, logistic regression analysis), TMPRSS2-ERG
rearrangement (P= 0.11, logistic regression analysis) or aggressive PCa (P= 1,
logistic regression analysis).
Transcriptome analysis and trigger score assessment. Benign (N= 63) and
tumor (N = 319) prostate tissues RNA-seq data with available FASTA ﬁles1, 9, 30
and matched genotype data were aligned to the reference genome hg19 using STAR
aligner31 and logarithm transformed (two based) RPKM+1 of each gene (UCSC
knownGenes) were computed using mrfQuantiﬁer32 and were quintile normalized.
For each functional variant, using matched normal RNA and genotype data, the
fraction of modulated DNA repair and hormone-regulated genes was quantiﬁed
from 459 sequenced transcripts (normalized RPKM greater or equal to 1 in at least
one individual was required). Seven-hundred eighty-seven variants with
monomorphic genotype in the benign samples set were excluded. Linear regression
of RPKMs across genotype classes, also grouped based on dominant model or
recessive model (dosage, dominant, or recessive test) was applied. Three genotype
classes were required to apply the dosage test and minimum of 3% per class for
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dominant and recessive. For each variant, the percentage of DNA repair and
hormone-regulated genes was computed as the highest percentage of associated
transcripts applying a false discovery rate (FDR) threshold of 5% and the
corresponding number of associated DNA repair and hormone-regulated genes
were then combined to compute the trigger score deﬁned as follows:
loge DnaRep ´HormReg þ 1ð Þ
Among the 21,364 functional variants considered in the study only 881 (~4%) had
a positive trigger score (Supplementary Data 3). Top ranked variants in the highest
tertile of positive trigger score distribution were retained for further analysis (N=
300). The relationship between the variants minor allele frequencies (MAF) and
trigger scores was investigated (Supplementary Fig. 14); no association detected.
For the 7p14.3 variant we then also performed genome-wide association
analysis considering 18,758 sequenced transcripts (all transcripts with normalized
RPKM greater or equal to 1 in at least one individual). Linear regression of RPKMs
across genotype classes using dosage model was performed applying a FDR
threshold of 5%. The variant was found genome-wide associated with other 1515
genes of which 723 (48%) show downregulation in presence of the minor allele
while 792 (52%) present upregulation.
DNA repair and hormone-regulated genes associated with 7p14.3 variant
(Supplementary Data 7) were tested for differential expression across SPOP mutant
and SPOP wild-type prostate adenocarcinomas using the Mann–Whitney test
statistics (Supplementary Fig. 2, P-value cutoff set at 1%).
Trigger score and prostate tissue speciﬁcity. RNA-seq data of 183 individuals
from 1000 Genomes Project with available FASTA ﬁles and matched genotype data
were aligned to the reference genome hg19 using STAR aligner31 and logarithm
transformed (two based) RPKM+1 of each gene (UCSC knownGenes) were
computed using mrfQuantiﬁer32 and were quintile normalized.
For each of the top selected trigger score variants (N = 300), we measured the
trigger score prostate speciﬁcity by comparing the score computed from the benign
prostate tissue samples and the score computed from the 1000 Genomes Project
samples. We performed 100 random sampling of 63 individuals from the 1000
Genomes Project samples set (to mimic the prostate tissue sample size) and
computed the trigger score for all top 300 variants. We then annotated a variant as
non-global, if no positive score was observed across the 100 experiments; a global
trigger score was annotated if at least one experiment provided a positive score.
A total of 69 (23%) variants showed non-global scores, where the score was positive
only in the prostate tissue dataset (see Supplementary Data 3). No association
between variants MAF and global or non-global annotations was detected.
Genotype/phenotype association analysis. Genotype/phenotype association
analysis was performed on the top selected trigger score variants (N= 300),
after excluding variants with genotyping call rate <85% (N= 423) (Supplementary
Data 5). Logistic regression analysis was used to test genotype/phenotype
associations and was performed using PLINK 1.0733 considering allelic, dominant
and recessive models. Dominant and recessive models were tested for the minor
allele. Association analyses were performed applying age and PSA correction as
available. In order to minimize genotype/phenotype-FDR, we computed multiple
rounds of discovery and validation by partitioning the whole data set in two subsets
two hundred times for each somatic phenotype (lesions in SPOP, TMPRSS2-ERG,
and FOXA1) by preserving the lesion incidence in each subset. Speciﬁcally, in each
partition the genotype/phenotype association was tested for the top selected var-
iants applying corrected P-value (FDR) cutoff at 20% and P-value cutoff at 5% for
discovery and validation, respectively. A genotype/phenotype association was
considered only if both thresholds were met.
Variant 7p14.3 genotypes were tested for association with total number of
tumor SNVs and with tumor genomic burden in 427 and 474 patients, respectively,
(data availability as per cBioPortal), using Mann–Whitney statistics. The tumor
genomic burden was measured as the fraction of the genome with absolute
log2(ratio) of tumor over normal above conventionally used threshold (0.15)
(Supplementary Fig. 1).
Protein–protein interaction analysis. To characterize the PPI network of the
transcriptome fraction modulated by the study variant, we ﬁrst built a reference
PPI network by merging information of ﬁve databases: BioGRID http://thebiogrid.
org/ (Release 3.2); HPRD http://www.hprd.org/ (Release 9 20100413); IntAct
http://www.ebi.ac.uk/intact/ (Release 20150120); MINT http://mint.bio.uniroma2.
it/mint/ (Release 20130326); STRING http://string-db.org/ (Release 9).
Interactions between nodes that represent human proteins and with a
conﬁdence score greater than 0.7 were retained (all HPRD interactions were
included because no score measure is associated to protein–protein interactions in
that database). The resulting network contains 263,369 interactions and 16,002
human proteins. The PPI network involving 7p14.3 variant-associated genes was
built from the reference PPI network and composed of 953 genes and 1755
interactions.
To determine how likely is that the fraction of the transcriptome modulated by
a variant reﬂects in a PPI network with a connected component comparable to the
7p14.3 variant network component, which is made of 552 genes and 1717
interactions (Supplementary Fig. 3), we built three distributions: (i) for each
functional variant considered in the study (i.e., functional variants in active
enhancers), the relative proportion of the biggest connected component present in
the corresponding induced PPI network was calculated and a reference distribution
was built; (ii) 10,000 random variants along the genome were selected (among all
variants available in the Affymetrix SNP 6.0 platform) and the relative proportion
of the biggest connected component present in corresponding induced PPI
network was calculated for each variant to build a reference distribution; and
(iii) using all genes from the reference PPI network (N= 16,002), 10,000 random
sets of size 953 were generated and the reference distribution of the relative
proportions of the biggest connected component present in the induced network
was built. P-values were then computed for 7p14.3 variant-induced network using
the three computed reference distributions (see Supplementary Fig. 4). Graphical
visualization of PPI networks was performed using both igraph library34 of R
programming language and Cytoscape tool35.
Pathway enrichment analysis was performed for the genes in the 7p14.3 variant
PPI connected component (N= 552) on the REACTOME pathway database36
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using ReactomePA R library37 (version 1.14.4). Oncogenes and tumor suppressors
(N= 57) targets enrichment was performed using permutation statistics based
on target genes information from TRRUST database15.
TF DNA-binding sites analysis. We collected 4920 unique TF DNA-binding sites
(TFBSs) consensus motifs from Jaspar38, HOMER39 and HOCOMOCO40 public
databases and from TRANSFAC Professional database41. We run the transcription
element search system (TESS)42 on the variant locus against the compiled
consensus motif collection to search for TFBSs. Both ancestral and minor alleles for
7p14.3 variant were separately tested considering 30 bp ﬂanking regions (length of
collected consensus motifs ranges between 5 and 30). For each tested TFBS
consensus motif, the TESS tool provides a set of log-likelihood-ratio-based scores.
Speciﬁcally, we used the score La, which represent the log-odds ratio of the match,
and the score Lm, which represents the maximum possible log-odds ratio for a
match from the given TFBS consensus motif. To select high conﬁdent results we
restricted the TFBS matches to La scores that are statistically signiﬁcant (P< 0.001)
if compared with a distribution of score matches computed from random regions
of the genome. Brieﬂy, given a consensus motif of length N> 6, we selected 10,000
random regions of length N (preserving uniqueness of the selected regions
sequence) across the human genome; for N< = 6 all possible sequences of length N
are considered (e.g., the number of possible sequence of length 5 is 45= 1024).
Then, of those TFBS that have signiﬁcant match (N= 32) in at least one of the two
tested conditions (variant locus with ancestral or minor allele), only those with
La/Lm score greater than 0.75 in at least one of the two conditions are ﬁnally
retained (N= 7). The list of TFBS consensus motifs across the variant is reported in
Supplementary Data 8. TFBS consensus motif search across a larger genomic
sequence around the variant to speciﬁcally identify other CEBPB and AR
motifs and possible CEBPB co-factors (c-MYC, MAFB, ONECUT1, HNF1A,
E2Fs, KFLs)17 was performed with the less stringent 0.005 P-value for La score
ﬁltering and the less stringent 0.6 La/Lm score cutoff; see Supplementary Data 8.
Linkage disequilibrium analysis. In all, 1000 Genome Project genotype data
of 1899 individuals from four populations (EUR, AFR, SAS, and EAS) was
considered. 54,892 variants within 1Mbp ﬂanking regions around rs1376350 were
analyzed. R^2 and D′ coefﬁcients of linkage disequilibrium between variant
rs1376350 and all other variants were computed using library genetics of R
programming language (http://CRAN.R-project.org/package=genetics). Variants
were annotated regarding their presence on the Affymetrix SNP 6.0 platform.
Variants with R^2> 0.10 were reported in Supplementary Data 6.
Cell lines. PC-3 (prostate cancer metastatic site derived, bone) and LNCaP
(prostate cancer metastatic site derived, lymph node) cells were maintained in
RPMI medium (Gibco, Life Technologies, Milan, Italy), supplied with 10% FBS,
100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-Glutamine, at 37 °C
with 5% CO2. Sex hormone depletion (androgens and estrogens), prior to DHT
(Sigma-Aldrich, Milan, Italy) treatments, was achieved by growing the cells in
medium without phenol red (Euroclone, Celbio, Milan, Italy), supplemented with
10% charcoal/dextran treated FBS (Hyclone, Celbio, Milan, Italy) for 48 h. The cell
lines were purchased from ATCC (American Type Culture Collection, LGC
Standards). PC-3 and LNCaP are GG at rs1376350 (GSM888588, GSM888346).
Plasmids and luciferase assay. The genomic sequence spanning 7p14.3 variant
was generated from PC-3 genomic DNA using primer pairs as detailed in
Supplementary Data 10. For the identiﬁcation of enhancer activity the fragment
was cloned in pGL4.26 (Promega) in which ﬁreﬂy luciferase is driven by a minimal
promoter. The PCR fragment was cloned upstream of the ﬁreﬂy luciferase gene
using Kpn1 and XhoI restriction enzymes. Constructs harboring the alternative
allele for the study variant (adenine) was created with the GeneArt Site-Directed
Mutagenesis System (Invitrogen, Life Technologies) according to the
manufacturer’s instructions. The correct insertion of the genomic sequence was
conﬁrmed by restriction enzyme digestion and sequence analysis (Euroﬁns
genomics). All plasmids were puriﬁed from DH5α E. coli bacterial cells using
the PureYield Plasmid Midiprep system protocol (Promega). The day before
transfection, PC-3 cells (8 × 104 cells) were seeded in 24-well plates. Cells
were transfected using TransIT-LT1 reagent (Mirus, TemaRicerca) with
pGL4.26-derived vector (350 ng). pRL-SV40 vector (50 ng) (Promega) was used to
normalize the transfections efﬁciency. Construct harboring cytosine allele showed
efﬁciency levels consistent with reference allele. In a parallel experiment, PC-3 cells
were cotransfected with pGL4.26-derived vector and pCMV-AR24Q
expression vector and/or pCMV6_CEBPB (100 ng, to over-express AR or CEBPB)
and treated with 100 nM DHT for at least 16 h. CEBPB or AR silencing was
performed by transfection of PC-3 or LNCaP cells with siRNA against CEBPB or
AR (20 nM) (FlexiTubeGeneSolution for CEBPB or AR, Qiagen) and Hiperfect
transfection reagent (Qiagen) or Lipofectamine 2000 (Thermo Fisher Scientiﬁc),
respectively. AllStars Hs Cell Death siRNA and AllStars Negative Control siRNA
(Qiagen) were used as positive and negative control (Supplementary Fig. 15).
Forty-eight hours after over-expression or 72 h after silencing, cells were lysed
using Passive Lysis Buffer 1X (Promega) and Fireﬂy and Renilla luciferase activities
were measured with Dual-Luciferase Reporter Assay (Promega) using the Inﬁnite
M200 multi-plate reader (Tecan).
ChIP assay. PC-3 cells were maintained into 150 mm Petri dishes in RPMI
medium without phenol red, supplemented with 10% charcoal/dextran treated
FBS. Two days after, as PC-3 cells do not express AR8, they were transfected either
with pCMV-AR24Q expression vector or with the pCMV-NeoBam empty vector.
Then, cells were treated with EtOH or DHT (100 nM) and after 16 h of treatment,
cells were subjected to ChIP with an anti-AR antibody (3 μg, 17-10489 ChIPAb +
androgen receptor Assay Kit, Millipore), anti-CEBPB antibody (3 μg, 18F8
Abcam), anti c-Myc antibody (3 μg, N262 Santa Cruz Biotechnology) or a normal
IgG (3 μg, CS200581), using the MagnaChIP HiSens ChromatIPKit (17-10461
Upstate, Millipore) as previously described8. Brieﬂy, the experiment procedure
includes chromatin crosslinking with formaldehyde, chromatin shearing for 45
cycles of 30 s ON/30 s OFF with the Bioruptor Pico (Diagenode), protein–DNA
complex immunoprecipitation and reverse crosslinking with protease K. Pre-
cipitated DNA was analyzed by real-time qPCR with KAPA SYBR FAST Universal
2X qPCR Master Mix (Kapa Biosystems, Resnova) using the CFX384 or CFX96
Detection Systems (BioRad). KLK3 enhancer region, IL-6 promoter region and
NPM1 intron 1 were used as positive control of AR, CEBPB and c-Myc, respec-
tively; a desertic region in chr12 as per ENCODE annotations (hg19,
chr12:17456963-17457066) was used as negative control. The region of interest
surrounding the 7p14.3 variant was ampliﬁed as well (Supplementary Data 10).
AR, CEBPB or c-Myc speciﬁc recruitment was calculated as enrichment respect to
the IgG according to the ΔCt method.
CRISPR-Cas9 7p14.3 deleted locus in PC-3 cells. Single guide RNA oligos
(sgRNAs) to induce 7p14.3 locus deletion were selected using the GPP Web Portal
(http://portals.broadinstitute.org/gpp/public/) that ranks candidates according to
their predicted on-target and off-target activity (Supplementary Data 9). Selected
sequences were ligated into pUC19 that contains U6 promoter-driven cassette,
derived from px330 (Addgene 42230). Plasmid eSpCas9(1.1)-2A-Puromycin,
derived from Addgene 71814, were generated through the addition of nucleotides
encoding 2 A peptide and Puromycin resistance43. To induce genomic deletions
four pairs of sgRNA (listed in Supplementary Data 9) vectors were cotransfected
with Cas9 expression vector. In a 6 well plate, 3 × 105 PC-3 cells/well were seeded
and after 24 h were transfected with 1.5 µg of eSpCas9(1.1)-2A-Puromycin plasmid
and 250 ng of sgRNA plasmid using FuGENE HD (Promega E2311). Three days
after transfection, cells were selected for 7 days with 2 µg/ml Puromycin (Sigma-
Aldrich P8833) in order to prioritize transfected cells only. A representative
amount of cells was used for DNA extraction and the remaining cells were re-
plated and cultured for RNAseq experiments. Genomic DNA was extracted fol-
lowing the procedures of NucleoSpinTissue kit (Macherey-Nagel). To evaluate the
editing, 25 µl PCR reaction was performed using 12.5 µl Platinum SuperFi Green
PCR Master Mix (2X), 50 ngDNA template and 0.5 µM forward and reverse pri-
mers (Supplementary Data 10). Predicted PCR bands (Supplementary Fig. 16),
veriﬁed by sequencing, are listed in Supplementary Data 9. Based on editing efﬁ-
ciency, combinations A and B were selected for downstream experiments (deleted
segments of length 625 bp and 731 bp, respectively).
RNA-seq experiments. PC-3 cells (7p14.3 deleted and not deleted cells) were
seeded in 24-well plate, transfected with pCMV-AR24Q expression vector using
FuGENE HD (Promega E2311) and then treated with DHT for at least 16 h.
CEBPB silencing was performed by transfection of PC-3 cells with siRNA against
CEBPB (20 nM) (FlexiTubeGeneSolution, Qiagen) and Lipofectamine RNAiMAX
Transfection Reagent (Invitrogen, 13778150). Total RNA was extracted using
the RNeasy kit (Qiagen) according to the manufacturer’s instructions. The
RNA integrity number (RIN) was quantify on the Agilent 2100 bioanalyzer.
cDNA libraries were prepared with TruSeq stranded mRNA library prep Kit
(RS-122-2101, Illumina) using 500 ng of total RNA. Single end (100 bp) sequencing
was performed on a HiSeq 2500 (Illumina). FASTA ﬁles were aligned to the
reference genome hg19 using STAR aligner31 and logarithm transformed (two
based) RPKM+1 of each gene (UCSC knownGenes) were computed using
mrfQuantiﬁer32 and were quintile normalized. The resulting expression data was
used to identify variation in gene expression in edited vs. control cells in all
treatment conditions (16 sample’s combinations) and across treatment conditions
for both edited and control cells separately (12 sample’s combinations). For each
combination, we considered transcripts with RPKM greater than 1 in at least one of
the two samples (values below 1 are set to 1) and selected only those with absolute
log2(ratio) equal or greater than 1. Concordance of deregulation in cells edited with
A and B sgRNAs combinations is shown in Supplementary Fig. 17 and deregulated
transcripts across experimental conditions in 731 bp edited cells (combination B)
are reported in Supplementary Data 11. Evidence of deregulation enrichment was
tested by comparing the abundance of deregulation in combinations B edited vs.
control cells and in control vs. control or edited vs. edited cells (Supplementary
Fig. 11). Hi-C data previously generated in RWPE1 prostate cells18 was queried
to test evidence of deregulation at chromosome 7 in correspondence of 7p14.3
Hi-C links (Fig. 3a, b). Hi-C links are deﬁned as genomic regions with normalized
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Hi-C signal above the 90th percentile of the overall intra-chromosomal 7p14.3
normalized Hi-C signal distribution (Supplementary Fig. 18).
Real-time qPCR. PC-3 cells were seeded in 6-well plate. Total RNA was extracted
using the RNeasy kit (Qiagen) according to the manufacturer’s instructions.
Two-hundred nanogram of total RNA was retro-transcripted into cDNA using the
Revert Aid First Strand cDNA Synthesis Kit (ThermoFisher Scientiﬁc). Then,
qPCR reactions in real-time were performed using KAPA SYBR FAST Universal
2X qPCR Master Mix (Kapa Biosystems, Resnova) using the CFX384 or CFX96
Detection Systems (BioRad). Analysis of relative mRNA expression was performed
using the ΔΔCt method with GAPDH (glyceraldehyde 3-phosphate dehy-
drogenase) as reference genes (primers sequences in Supplementary Data 10).
RNA-seq validation of selected transcripts (Supplementary Data 10) was performed
with qPCR including RAB1B, BAP1, and BCAP31 as negative controls. As control
cells, we used PC-3 transfected with pSpCas9(1.1)43, sgRNA_scramble, and
pGL4.14. After 72 h from transfection, cells were selected with Puromycin for
4 days and harvest for 4 weeks.
Western blot. Proteins were extracted from PC-3 cells with ice-cold RIPA (Radio
Immuno-Precipitation Assay) lysis buffer supplemented with protease inhibitor
cocktail (11873580001, Roche), then homogenized in a dounce homogenizer for 1 h
and centrifuged at 13,400 rcf at 4 °C for 10min. The supernatants were collected and
boiled with 6x sample buffer at 95 °C for 5min. The samples were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to nitro-
cellulose membranes using wet transfer or the semi-dry iBlot Transfer System (Invi-
trogen, Life Technologies). The membranes were blocked with 5% non-fat dry milk in
PBS-T for 1 h, then incubated with either anti-CEBPB (Abcam 18F8, 1:1000 dilution),
anti-AR (Cell Signaling 5153 S, 1:1000 dilution), anti-c-Myc (Santa Cruz
N262,1:1000), anti-GAPDH (Santa Cruz Biotechnology, sc-322330 dilution) or anti-
beta-Tubulin (Santa Cruz Biotechnology 3F3-G2, 1:8000 dilution) antibody in 1%
non-fat dry milk in PBS-T overnight at 4 °C. Membranes were then incubated with
secondary goat anti-mouse (Santa Cruz Biotechnology A9044, 1:10000) or goat anti-
rabbit antibodies (Sigma-Aldrich A9169, 1:12,000) for 1 h at room temperature.
Detection was achieved using the ECL Select detection reagent (Amersham, GE Health
Care) with the ChemiDoc XRS + System (BioRad) (Supplementary Figs. 19 and 20).
Data availability. RNA-seq data of control and edited PC-3 cells have been
deposited at BioProject database under the accession code PRJNA381797. All other
remaining data are available within the article and Supplementary Files, or
available from the authors upon request.
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